NEW YORK, Dec. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=116392&from=4CLASS PERIOD: May 10, 2024 to October 1 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Dec. 12, 2024 /PRNewswire/ ...

NEW YORK, Dec. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=115945&from=4CLASS PERIOD: May 10, 2024 to October 1 ...

NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Humacyte, Inc. investors who were adversely affected by alleged securities fraud between May 10, 2024 and October 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/humacyte-inc-laws ...

NEW YORK, Dec. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=114728&from=4CLASS PERIOD: May 10, 2024 to October 17 ...

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=114511&from=3 CLASS PERIOD: May 10, 2024 to O ...

Core Viewpoint - Robbins LLP has filed a class action on behalf of investors who purchased Humacyte, Inc. securities between May 10, 2024, and October 17, 2024, alleging that the company misled investors regarding its manufacturing practices and the status of its Biologic License Application (BLA) for its acellular tissue engineered vessel [1][2][3]. Group 1: Allegations and Impact - Humacyte is engaged in the development of Acellular Tissue Engineered Vessel (ATEV), a lab-grown blood vessel implant [2]. - On August 9, 2024, Humacyte announced that the FDA required additional time to review its BLA, leading to a stock price decline of $1.29, or 16.4%, closing at $6.62 per share on August 12, 2024 [2]. - On October 17, 2024, the FDA issued a Form 483 revealing violations at Humacyte's Durham facility, including lack of microbial quality assurance and inadequate quality oversight, causing the stock price to drop by $0.95, or 16.35%, to close at $4.86 per share [2][3]. Group 2: Disclosure Failures - The complaint alleges that Humacyte failed to disclose that its Durham facility did not comply with good manufacturing practices, which included quality assurance and microbial testing [3]. - It is claimed that the company did not inform investors that the FDA's review of the BLA would be delayed due to the need for remediation of these deficiencies [3]. - The allegations suggest that there was a substantial risk to the FDA approval of ATEV for vascular trauma as a result of these undisclosed issues [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their applications by January 17, 2025 [4]. - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 4: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]. - The firm has a history of recovering over $1 billion for shareholders and is recognized for its commitment to shareholder rights litigation [5].

DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat presentation at the Piper Sandler 36th Annual Healthcare Conference, in New York, NY on Thursday, December 5, 2024. Management will also be available for one-on-one m ...

NEW YORK, Dec. 2, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Humacyte, Inc. investors who were adversely affected by alleged securities fraud between May 10, 2024 and October 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/humacyte-inc-lawsuit-sub ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Nov. 26, 2024 (GLOBE N ...